Primary intracranial sarcoma associated with DICER1 mutant: a case report and preclinical investigation
Brain Tumor Pathology · 2025
DOI: 10.1007/s10014-024-00495-8 ↗Kurz gefasst
Fallbericht in der Zeitschrift Brain Tumor Pathology, 2025. Verfasst von Hirokuni Honma und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa, Yokohama, 2360004, Japan. Hauptthemen laut MEDLINE: Ribonuclease III, DEAD-box RNA Helicases, Brain Neoplasms, Sarcoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Primary intracranial sarcoma (PIS) is a rare and aggressive pediatric brain tumor, which is partially associated with DICER1 mutant. Although the molecular genetic characteristics of this tumor have previously been investigated, novel therapeutic targets remain unclear. Further, the lack of faithful preclinical models has hampered the development of novel therapeutic strategies. Herein, we describe a pediatric case of PIS with DICER1 mutant and describe the development of the first novel patient-derived xenograft (PDX) model of this rare tumor. Somatic genomic profiling of the tumor revealed mutations in DICER1, TP53, and ATRX. Germline analysis further revealed a pathogenic variant of DICER1, significant for the diagnosis and management of hereditary tumor predisposition syndrome. Overall, we demonstrated that the PDX model faithfully retained the phenotype and genotype of the patient's tumor, as well as the DNA methylation profile. Through high-throughput drug screening using PDX tumor cells, we found that activation of the retinoic acid receptor (RAR) signaling pathway reduced tumor cell viability. These findings indicate that the RAR signaling pathway is a potential therapeutic target for PIS in DICER1 mutant.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa, Yokohama, 2360004, Japan.
- Neurosurgical-Oncology Laboratory, Yokohama City University, Yokohama, Japan.
- Department of Neurosurgery, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa, Yokohama, 2360004, Japan. ktate12@yokohama-cu.ac.jp.
- Neurosurgical-Oncology Laboratory, Yokohama City University, Yokohama, Japan. ktate12@yokohama-cu.ac.jp.
- Laboratory of Biopharmaceutical and Regenerative Science, Graduate School of Medical Science, Yokohama City University, Yokohama, Japan. ktate12@yokohama-cu.ac.jp.
- Department of Pathology, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Honma, H., Tateishi, K., Iwashita, H., Miyake, Y., Tsujimoto, S., Hayashi, H., Ohgaki, F., Nakano, Y., Ichimura, K., Yamanaka, S., Kato, M., Fujii, S., Ito, S., Yokoo, H., & Yamamoto, T. (2025). Primary intracranial sarcoma associated with DICER1 mutant: a case report and preclinical investigation. Brain Tumor Pathology. https://doi.org/10.1007/s10014-024-00495-8
Vancouver
Honma H, Tateishi K, Iwashita H, Miyake Y, Tsujimoto S, Hayashi H, et al. Primary intracranial sarcoma associated with DICER1 mutant: a case report and preclinical investigation. Brain Tumor Pathology. 2025. doi:10.1007/s10014-024-00495-8
BibTeX
@article{Honma2025,
author = {Honma, Hirokuni and Tateishi, Kensuke and Iwashita, Hiromichi and Miyake, Yohei and Tsujimoto, Shinichi and Hayashi, Hiroaki and Ohgaki, Fukutaro and Nakano, Yoshiko and Ichimura, Koichi and Yamanaka, Shoji and Kato, Motohiro and Fujii, Satoshi and Ito, Shuichi and Yokoo, Hideaki and Yamamoto, Tetsuya},
title = {Primary intracranial sarcoma associated with DICER1 mutant: a case report and preclinical investigation},
journal = {Brain Tumor Pathology},
year = {2025},
doi = {10.1007/s10014-024-00495-8}
}
EUVIMED